Conditioning therapy in connection with haematopoietic SCT (HSCT) induces a disruption of the intestinal barrier function facilitating the permeation of bacteria and endotoxin through the bowel wall with subsequent increased risk of septicaemia and a worsening of GVHD in the allogeneic setting. Palifermin (recombinant human keratinocyte growth factor) reduces the severity of oral mucositis with HSCT. The present trial investigates its effect on intestinal barrier function. Seventeen lymphoma patients undergoing autologous HSCT received palifermin. Intestinal permeability was assessed before the conditioning therapy and on days þ 4 and þ 14. Clinical oral and gastrointestinal toxicity was prospectively assessed in parallel. A comparison was made with matched historical study patients (n ¼ 21). Patients treated with palifermin had a significantly better preserved intestinal barrier function (P ¼ 0.01 on day þ 4) and were in less need of total parenteral nutrition (P ¼ 0.005) as compared with controls. No significant reduction of clinical gastrointestinal or oral toxicity was observed. The intestinal barrier function, normally disrupted by the conditioning therapy, is preserved by palifermin. Whether intestinal barrier preservation protects from invasive infections, and in the allogeneic setting diminishes GVHD severity, remains to be investigated in randomized controlled trials.
Introduction
Haematopoietic SCT (HSCT) is a standard treatment option for a variety of haematological malignancies, but is afflicted with significant toxicity from the mouth and gastrointestinal tract. The incidence and severity of toxicity vary with the conditioning regimen.
It is a well-known fact that conditioning therapy induces a disruption of the intestinal barrier function during HSCT, 1, 2 facilitating the permeation of bacteria and endotoxin through the bowel wall with subsequent septicaemia and release of cytokines, known to be important mediators of GVHD, the primary complication of allogeneic HSCT.
Intervention trials have focused mainly on oral toxicity. 3 One of the tested substances is human recombinant keratinocyte growth factor (palifermin; Kepivance, Amgen, Thousand Oaks, CA, USA). Palifermin has been found to reduce chemotherapy-and radiation-induced injury to the mucosal lining in the oral cavity and in the lower gastrointestinal tract in animal models. 4, 5 In patients, a significant reduction of severe oral toxicity has been observed after TBI-containing conditioning. 6 However, the eventual protective properties of palifermin on the lower gastrointestinal tract in humans have not yet been studied. The primary objective of this study was to determine whether palifermin might ameliorate intestinal barrier function in patients undergoing autologous HSCT after chemotherapy-containing conditioning therapy. The secondary objectives were to evaluate the incidence and severity of clinical oral and gastrointestinal toxicity in the two study groups.
Patients and methods

Patients
Eligible patients were between 18 and 70 years of age with no history of prior oral or gastrointestinal disease or present symptoms from the mouth or the gastrointestinal tract, had a diagnosis of lymphoma and were referred for autologous HSCT with BEAM conditioning (BCNU 300 mg/m 2 Â 1 on day À6, etoposide 300 mg/m 2 Â 1 on days À5 to À2, ara-C 200 mg/m 2 Â 2 on days À5 to À2 and melphalan 140 mg/m 2 Â 1 on day À1). Seventeen patients were included between June 2006 and March 2008. These patients received a standard dose of palifermin.
The control group (n ¼ 21) not receiving palifermin consisted of patients included in a research programme investigating gastrointestinal toxicity in connection with BMT. Eight of these patients were included in an observational study 7 published earlier, and the other 13 patients fulfilled the inclusion criteria for the research programme but were excluded because of missing data. However, prospectively collected data for oral and intestinal toxicity and for 51 Cr-EDTA-resorption were available. The control patients were enrolled between April 1998 and March 2002, and they were all conditioned with BEAM and had a diagnosis of lymphoma. They did not receive any interventional agent with potential gut-protective properties such as, for example, glutamine or amifostine. Details of patient characteristics and treatment are given in Table 1 . The study protocols were approved by the Ethical Committee and the Isotope Committee of Sahlgrenska University Hospital, and all 38 patients gave informed written consent before inclusion.
Methods
All patients (n ¼ 38) were conditioned with BEAM followed by the infusion of autologous haematopoietic stem cells on day 0. They all received the same prophylactic antibiotics in the form of orally administered ciprofloxacin 1000 mg/day from day À5 until engraftment (the first of 3 consecutive days with WBC X1.0 Â 10 9 /l), fluconazole 200 mg/day from day À7 to day þ 28, aciclovir 800-1200 mg/day from day À7 to day þ 180 and trimethoprim/sulphamethoxazol from day À7 to day À1 and from engraftment to day þ 180. All patients received antiemetic therapy (ondansetron) during the conditioning therapy.
Total parenteral nutrition was generally started when the daily oral caloric intake decreased below 50% of the basic needs and was tapered off and stopped when the daily caloric intake exceeded 50% of the basic needs.
Intestinal permeability was assessed by a 51 Cr-EDTA absorption test 8 before the start of conditioning (on day À10) and 4 (on day þ 4) and 14 (on day þ 14) days after stem cell infusion. The 24-h urinary excretion of 51 Cr-EDTA was expressed as a percentage of the dose given orally.
The palifermin group (n ¼ 17) received 60 mg/kg of palifermin (Kepivance) i.v. once daily during 3 days before (days À9 to À7) and after (days 0 to þ 2) the conditioning therapy.
Clinical gastrointestinal toxicity (nausea/vomiting and diarrhoea) as well as oral toxicity was graded prospectively on a daily basis from day À10 until resolution of symptoms according to the World Health Organizations (WHO) 9 by a study nurse and a dentist, respectively.
Statistics
If not otherwise stated, data are expressed as medians and ranges. The Mann-Whitney U-test was used for significance calculations of differences between groups. Fisher's exact test was used when comparing observed frequencies between groups. A P-value of o0.05 was considered statistically significant. The number needed to study the ability to detect a significant difference in intestinal permeability between the groups was based on the assumption that maximal intestinal permeability expressed as the percentage of 51 Cr-EDTA resorption would decrease by 40% among palifermin-treated patients compared with controls (significance level of 5 and 80% power).
Results
Study groups
There were no statistical differences regarding the basic clinical characteristics between the study groups ( Table 1) .
Intestinal barrier function
Intestinal barrier function was significantly preserved on day þ 4 in patients receiving palifermin as compared with controls ( Figure 1) . Baseline values were within normal range in all patients in both study groups. Missed values at baseline (n ¼ 5 and 4 in controls and palifermin patients, respectively) and on day þ 4 (n ¼ 6 and 1 in controls and palifermin patients, respectively) were in all cases due to accidentally lost urine portions. On day þ 14 (n ¼ 13 and 12 in controls and palifermin patients, respectively), missed values were due to discharge of patients before day þ 14 (n ¼ 12) and accidentally lost urine portions (n ¼ 13).
Palifermin administration
Fifteen patients received all six scheduled doses of palifermin and two patients received three doses. In both cases, patients refused the last three doses because of side effects (taste alteration and rash/pruritus, respectively). These patients are included in the intention-to-treat analysis in the palifermin-group, but when analysed separately, they had a significantly increased 51 Cr-EDTA resorption on day þ 4 compared with patients receiving all six scheduled doses (data not shown).
Palifermin was well tolerated and no already known side effects were observed. Intestinal toxicity According to the WHO, clinical intestinal toxicity was evaluated in all patients (n ¼ 38). There were no significant differences between the groups with respect to the proportion of patients with WHO toxicity grades 3 and 4, but palifermin-treated patients were discharged earlier and were in less need of total parenteral nutrition compared with controls (Table 2) .
Oral toxicity
According to the WHO, oral toxicity was evaluated in all patients. No difference with respect to the proportion of patients with toxicity grades 3 and 4 was observed between the groups (Table 2 ).
Discussion
It is by now a well-known fact that the intestinal barrier is disrupted by the myeloablative conditioning therapy in connection with HSCT. The main finding in the present trial was that the intestinal barrier was preserved by palifermin in patients undergoing autologous HSCT after myeloablative chemotherapy. This was not a randomized trial but the result may still attach importance, as the inclusion criteria and the study protocols were identical for the two study groups despite the fact that almost 7 years have elapsed between the protocols. It is true that changes in treatment philosophy might have an influence on soft end points such as, for example, discharge day, but it is unlikely that such changes Cr-EDTA expressed as a percentage of the dose given orally, % ± s.e.m.) in the two study groups (P ¼ 0.01 on day þ 4).
Table 2
Clinical outcomes in the two study groups explain the preservation of the intestinal barrier in the palifermin-treated patients. There are several different methods evaluating intestinal barrier function. The 51 Cr-EDTA resorption test used in the present trial has been shown to be reliable, as absorption data are not affected by potential confounding factors such as renal function, body mass index, urinary volume or small-bowel transit time. 7, 10 The disruption of the intestinal barrier facilitates the permeation of bacteria and endotoxin through the bowel wall with subsequent risk of septicaemia.
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In the present trial, there was no difference in the frequency of blood stream infections as between the study groups despite a better preserved intestinal barrier function among palifermin-treated patients. This may be explained by the fact that the study was not designed (owing to small numbers) to detect such a difference and that bacterial translocation is influenced by several other factors not evaluated in this trial. However, not even in the much larger randomized study by Spielberger et al. 6 was any significant reduction of blood stream infections observed in palifermin-treated patients despite a highly significant reduction of severe oral toxicity. This suggests that bacterial translocation is influenced by factors other than oral mucositis. One such factor may be intestinal barrier disruption, which was not evaluated in the randomized trial, but it may be anticipated that there actually was a significant intestinal barrier disruption as 25% of the patients in the placebo group were reported to have blood stream infections (14% in our study). Therefore, it may be speculated that palifermin does have the potential to protect from gut injury, but that it is not strong enough to protect from damage of the magnitude that is induced by a high-intensity TBI-containing conditioning therapy.
Currently, it is unknown which patients will benefit most by palifermin prophylaxis, and the optimal dose and dose scheme remain to be studied. An interesting finding in this respect was that the patients in this trial, who only received three doses of palifermin, had a significantly more pronounced intestinal barrier dysfunction compared with those patients who received all six scheduled doses.
There was no significant difference in the frequency of severe oral mucositis (grades 3 and 4 according to the WHO) as between the study groups. The most probable explanation might be that thist study was too small to be able to detect such a difference. In the pivotal study by Spielberger et al., 6 the effect of palifermin on oral mucositis was studied in patients receiving a much more toxic preparative regimen than BEAM conditioning. The proportion of patients with severe mucositis was 98% in the placebo group, whereas the corresponding proportion in this trial was only 29%. However, an alternative explanation might be that BEAM conditioning is not toxic enough to benefit from palifermin prophylaxis. It would have been interesting to compare other clinical parameters such as, for example, the use of narcotic analgesics and toxicity according tograding systems other than the WHO, but prospective data were missing in the control group.
In the allogeneic setting, it has been shown in murine models that the gut is not only a major target organ for GVHD, but also a critical amplifier of systemic GVHD severity. An intensification of the conditioning treatment causes aggravated intestinal damage, increased bacterial translocation, and subsequently increases the severity of systemic acute GVHD. Endotoxin is a constituent of normal bowel flora with the ability to stimulate the release of inflammatory cytokines known to be important mediators of clinical [12] [13] [14] and experimental GVHD. [15] [16] [17] Endotoxin most likely permeates into the systemic circulation through the intestinal barrier, which is disrupted by the conditioning treatment. 18, 19 Accordingly, diminished GVHD has been achieved with palifermin through its gut-protective properties. [20] [21] [22] These murine data have been supported in clinical uncontrolled trials suggesting that intestinal barrier disruption correlates to acute GVHD severity 23 and that GVHD is diminished with palifermin, 24 but in a third trial, palifermin did not have any influence on GVHD severity. 25 Thus, there is some evidence that palifermin may also have GVHD protective properties in patients, but these preliminary data need to be confirmed in prospective randomized trials evaluating different dose schemes of palifermin and include patients receiving conditioning regimens of different intensity.
